Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8942018 | 0.79 | TSHR (0.58) | MAPTTSHRGLALMNASMN1; SMN2 | |
| SCHEMBL16014624 | 0.77 | TSHR (0.47) | MAPTTSHRGLALMNASMN1; SMN2 | |
| SCHEMBL15557472 | 0.73 | DHFR (0.31) | MAPTTSHRLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2089785 | 0.73 | FLT3 (0.47) | MAPTLMNACA1CA2CA12 | |
| SCHEMBL18009414 | 0.72 | KDM4E (0.56) | MAPTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL15557356 | 0.72 | RAB9A (0.57) | MAPTTSHRLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL17394134 | 0.71 | NUDT1 (0.40) | MAPTTSHRLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL27789493 | 0.71 | CHRNB2 (0.40) | MAPTTSHR | |
| SCHEMBL15556958 | 0.70 | LMNA (0.46) | GLALMNACA1CA2CA12 | |
| SCHEMBL15556633 | 0.68 | MEN1 (0.33) | MAPTLMNACA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | NYSNOBIO IRELAND DAC (IE) | 2021-08-12 | — | — | US | disclosed |
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | NYSNOBIO IRELAND DAC (IE) | 2021-08-12 | — | — | US | disclosed |
| US-20210230126-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2021-07-29 | — | — | US | disclosed |
| US-10889553-B2 | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same | NYSNOBIO IRELAND DAC (IE) | 2021-01-12 | — | — | US | disclosed |
| US-20200172497-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2020-06-04 | — | — | US | disclosed |
| US-10308617-B2 | Triazole benzamide derivatives and the compositions and methods of treatment regarding the same | An2H Discovery Limited (IE) | 2019-06-04 | — | — | US | disclosed |
| EP-3463347-A1 | TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | An2H Discovery Limited (IE) | 2019-04-10 | — | — | EP | disclosed |
| US-20180118697-A1 | TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118697-A1 | TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2018-05-03 | — | — | US | disclosed |
| WO-2017210694-A1 | TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | An2H Discovery Limited (IE) | 2017-12-07 | — | — | WO | disclosed |
| EP-2387395-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8040491-B2 | Exposure method, substrate stage, exposure apparatus, and device manufacturing method | NIKON CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118697-A1 | TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | PINK1, ATG7, ADRM1 | MAPT 1275/4885TSHR 2641/4885GLA 3010/4885 |
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | TP53, RB1, CDK1 | MAPT 3369/4885TSHR 2732/4885GLA 3081/4885 |
| US-20200172497-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | ATG7, PINK1, ADRM1 | MAPT 1670/4885TSHR 2615/4885GLA 3384/4885 |
| US-20210230126-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | ATG7, PINK1, ADRM1 | MAPT 1670/4885TSHR 2615/4885GLA 3384/4885 |
| US-10308617-B2 | Triazole benzamide derivatives and the compositions and methods of treatment regarding the same | PINK1, ATG7, ADRM1 | MAPT 1275/4885TSHR 2641/4885GLA 3010/4885 |
| US-10889553-B2 | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same | ATG7, PINK1, ADRM1 | MAPT 1670/4885TSHR 2615/4885GLA 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.